AWMSG medicines approvals
Infliximab biosimilars Inflectra (Hospira) and Remsima (Celltrion) have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG). Both can be used for any licensed indication in accordance with AWMSG or National Institute for Health and Care Excellence guidance and should be prescribed by brand. The group has also approved lurasidone (Latuda; Sunovion) to treat adults with schizophrenia and Anoro Ellipta (umeclidinium and vilanterol; GlaxoSmithKline) to relieve symptoms in chronic obstructive pulmonary disease. See the AWMSG website for full details of restrictions.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068126
Recommended from Pharmaceutical Press